The first of these, (1) gemtuzumab ozogamicin (Mylotarg®; an anti-CD33 mAb linked to calicheamicin), for the treatment of acute myelogenous leukemia (AML) was approved in 2000 under the FDA accelerated-approval process [3]. This evidence concerns the gene CD33 and acute myeloid leukemia.